Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

88.9%

8 terminated/withdrawn out of 9 trials

Success Rate

11.1%

-75.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

6 terminated

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

3(33.3%)

Early Phase 1

1(11.1%)

9Total

Phase 1(5)

Phase 2(3)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03935568Phase 1Terminated

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

Role: lead

NCT03371420Early Phase 1Terminated

PET Imaging of Subjects Using 124I-PU-AD

Role: lead

NCT04782609Phase 1Terminated

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma

Role: lead

NCT04311515Phase 2Terminated

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Role: lead

NCT03935555Phase 1Terminated

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Role: lead

NCT04505358Phase 2Withdrawn

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis

Role: lead

NCT03373877Phase 1Terminated

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Role: lead

NCT05612633Phase 2Withdrawn

A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

Role: lead

NCT03166085Phase 1Completed

PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer

Role: collaborator

All 9 trials loaded